CDK2 and renal cell carcinoma: Nobiletin had no effect on CDK2, CDK4, and cyclin D1 levels, but reduced the expressions of p-CDK2, RB, and p-RB levels with increasing doses, in RCC cell lines (Figure 3A and Supplementary Figure S2A), indicating that G1/S transition was blocked.